Kintor Pharmaceutical Limited (KNTPF)
OTCMKTS · Delayed Price · Currency is USD
0.3643
+0.0349 (10.60%)
At close: Aug 18, 2025
Kintor Pharmaceutical Employees
Kintor Pharmaceutical had 168 employees as of December 31, 2024. The number of employees decreased by 57 or -25.33% compared to the previous year.
Employees
168
Change (1Y)
-57
Growth (1Y)
-25.33%
Revenue / Employee
$4,077
Profits / Employee
-$126,640
Market Cap
138.55M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 168 | -57 | -25.33% |
Dec 31, 2023 | 225 | -76 | -25.25% |
Dec 31, 2022 | 301 | -15 | -4.75% |
Dec 31, 2021 | 316 | 114 | 56.44% |
Dec 31, 2020 | 202 | 57 | 39.31% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 68 |
American Oncology Network | 1,914 |
CytoDyn | 13 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
Kintor Pharmaceutical News
- 2 years ago - Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA - PRNewsWire
- 2 years ago - Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US - PRNewsWire
- 2 years ago - Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China - PRNewsWire
- 2 years ago - Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023 - PRNewsWire
- 2 years ago - Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound - PRNewsWire